Tirzepatide ���子背景与靶点 — Quick Reference

By Editorial Desk · published 2026-05-18 · last reviewed 2026-06-13 · Data

This is a working overview of peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Background And Receptor Pharmacology

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide at a glance

Analytical Methods, Stability and Verification

Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.

Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.

Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.

Related pages on this site

• Portable update
• Focused trends
• Balanced playbook
• Quality dataset
• Verified reference
• Measured review
• Modular handbook
• Portable primer

Analytical Characterisation and Storage Practice

Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.

Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Background and Dual Receptor Pharmacology

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Supporting material

==== Amino acid substitution models ==== For many analyses, particularly for longer evolutionary distances, the evolution is modeled on the amino acid level. Since not all DNA substitution also alter the encoded amino acid, information is lost when looking at amino acids instead of nucleotide bases. However, several advantages speak in favor of using the amino acid information: DNA is much more inclined to show compositional bias than amino acids, not all positions in the DNA evolve at the same speed (non-synonymous mutations are less likely to become fixed in the population than synonymous ones), but probably most important, because of those fast evolving positions and the limited alphabet size (only four possible states), the DNA suffers from more back substitutions, making it difficult to accurately estimate evolutionary longer distances. Unlike the DNA models, amino acid models traditionally are empirical models. They were pioneered in the 1960s and 1970s by Dayhoff and co-workers by estimating replacement rates from protein alignments with at least 85% identity (originally with very limited data and ultimately culminating in the Dayhoff PAM model of 1978). This minimized the chances of observing multiple substitutions at a site. From the estimated rate matrix, a series of replacement probability matrices were derived, known under names such as PAM250.

=== Affinity Chromatography === Affinity chromatography exploits the specific interactions between proteins and their ligands. A target protein is captured on a column containing a ligand that specifically binds to it, such as an antibody, enzyme substrate, or metal ion. After washing away non-specifically bound proteins, the target protein is eluted using a solution that disrupts the protein-ligand interaction. This method provides high specificity and is often used for purifying recombinant proteins that have affinity tags.

=== Research === The company has more than 1,200 researchers working across its 12 Research & Development centers around the world. The company is focused on the development of potential new treatment options derived both from human plasma as well as a new class of recombinant antibody drugs. Grifols is researching a number of pathologies – from immunodeficiencies to respiratory disorders to age-related conditions – to create new therapeutics. It is also developing new diagnostics for blood screening.

== Recalls and safety corrections == In 2014, Tandem recalled selected lots of t:slim cartridges because leaks could cause too much or too little insulin to be delivered. In 2024, the FDA classified a correction of version 2.7 of the iOS t:connect app as a Class I recall. Repeated app crashes and automatic relaunches could increase Bluetooth communication, drain a connected t:slim X2 battery and interrupt insulin delivery. The action covered 85,863 distributed app installations; the FDA reported 224 injuries and no deaths as of April 15, 2024. Tandem released updated app versions and advised users to monitor pump batteries. In April 2025, the FDA classified a correction of Control-IQ+ software version 7.9 as a Class I recall. A defect affecting 85 pumps could incorrectly interpolate glucose values after gaps in CGM data and cause too much or too little insulin to be delivered. Tandem instructed affected users to turn off Control-IQ+ until the software was corrected. Later in 2025, Tandem issued two further corrections that the FDA classified as Class I recalls. One covered 171,750 t:slim X2 pumps whose speakers could fail and stop insulin delivery; the company reported 59 injuries and no deaths. The other covered 17,745 Mobi pumps that could falsely detect vibration-motor failure and enter a non-operational state, stopping insulin delivery and CGM sessions. Tandem directed users to install corrected pump software.

==== Fluorocarbons ==== Fluorocarbons and especially perfluorocarbons are excellent substrate materials for the creation of superhydrophobic surfaces due to their extremely low surface energy. These materials are synthesized by replacing hydrogen atoms with fluorine atoms of a hydrocarbon.

Sources: en.wikipedia.org

Supporting material

The Houthis stepped up their pressure on Hadi's weakened government, seizing the presidential palace and strategic military installations in Sanaa and shelling the president's private residence on 20 January. The following day, they took control of Hadi's home, stationing armed guards outside to keep him under virtual house arrest. Hadi, Prime Minister Khaled Bahah, and the cabinet resigned the following day, saying they could not continue to work under the conditions the Houthis had imposed. The rebel group welcomed Hadi's resignation, but continued to keep him under house arrest. The news prompted four southern governorates to announce they would disregard all orders from Sanaa. The House of Representatives was to meet on 25 January to discuss whether to accept or reject Hadi's resignation under the Yemeni constitution, but the session was cancelled after the Houthis took control of the parliament building. The United Nations stepped in to attempt a negotiated resolution to what many in Yemen regarded as a Houthi coup. UN negotiations were fruitless, and a Houthi ultimatum to Yemen's political factions to find a solution was not met. On 6 February, the Houthis declared themselves in total control of the Yemeni government, dissolving parliament and installing a Revolutionary Committee led by Mohammed Ali al-Houthi to lead the state in an interim capacity. The announcement sparked protests in Sanaa and other cities, especially in the south.

== Genes == In humans, the gene for the alpha subunit is located at cytogenetic location 6q14.3. It is expressed in two cell types, most notably the basophils of the anterior pituitary. The gene for the FSH beta subunit is located on chromosome 11p13, and is expressed in gonadotropes of the pituitary cells, controlled by GnRH, inhibited by inhibin, and enhanced by activin.

==== In animals ==== PABA has been referred to historically as "vitamin Bx", but plays no direct role in animal cells and is hence no longer recognized as a vitamin. Animals (including humans) are unable to use PABA in any way and so require folate from dietary sources such as green leafy vegetables. PABA can play a role in the supply of folate to an animal via its microbiome; this is best demonstrated in the worm C. elegans, in which addition of PABA could increase folate production by resident E. coli and correct for deficiencies. The C. elegans folate transporter only works with the reduced form (tetrahydrofolate, THF and derivatives such as folinic acid), not regular folic acid. Any folic acid from the environment is only usable following spontaneous breakdown to PABA-glu, which E. coli uses to make THF. In contrast, humans can directly use oxidized folates thanks to the proton-coupled folate transporter and have no need for this detour; this "recycling" of PABA-glu would, at best, compensate for folate degradation. The above do not seem to apply in normal mammals, however. Despite detection of gut-produced folate being incorporated into mammals, ex vivo folate synthesis capacity of fecal bacteria have no correlation with the folate status of their donors. Furthermore, comparison with germ-free animals show that under a chow diet, the mouse microbiome is a net consumer of folate. The caveat is that the mouse chow is more folate-rich than typical human diets and may be encouraging a shift towards a folate-consuming microbiome.

== Structural studies == As of late 2007, 12 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1EVY​, PDB: 1EVZ​, PDB: 1JDJ​, PDB: 1M66​, PDB: 1M67​, PDB: 1N1E​, PDB: 1N1G​, PDB: 1WPQ​, PDB: 1X0V​, PDB: 1X0X​, PDB: 1YJ8​, and PDB: 1Z82​.

Sources: en.wikipedia.org

Supporting material

=== Mechanisms of iron regulation === Human iron homeostasis is regulated at two different levels. Systemic iron levels are balanced by the controlled absorption of dietary iron by enterocytes, the cells that line the interior of the intestines, and the uncontrolled loss of iron from epithelial sloughing, sweat, injuries and blood loss. In addition, systemic iron is continuously recycled. Cellular iron levels are controlled differently by different cell types due to the expression of particular iron regulatory and transport proteins.

== Past events == In the 19th and early 20th centuries asbestos was used in many products and in building construction and was not considered a threat to human health or the environment. Deaths and lung problems caused by asbestos were first documented in the early 20th century. The first regulations of the asbestos industry were published in the UK in the 1930s. Regulation of asbestos in the US did not occur until the 1980s. In the 1970s there was a serious issue with the water treatment infrastructure of some US states, notably in Southern California with water sourced from the Sacramento–San Joaquin River Delta. Water was being disinfected for domestic use through chlorine treatment, which was effective for killing microbial contaminants and bacteria, but in some cases, it reacted with runoff chemicals and organic matter to form trihalomethanes (THMs). Research done in the subsequent years began to suggest the carcinogenic and harmful nature of this category of compounds. EPA issued its first standard for THMs, applicable to public water systems, in 1979, and more stringent standards in 1998 and 2006. Rapid industry changes also make the treatment and regulation of CEC particularly challenging. For instance, the replacing substance (GenX), for the recently regulated perfluorooctanoic acid (PFOA), a PFAS, had a more detrimental environmental impact, resulting in the subsequently banning of GenX as well. Hence, there is a pressing need for the treatment and management of CEC to keep up with global trends.

=== Dopamine and G-protein coupling === During mania, there is an increase in neurotransmission of dopamine that causes a secondary homeostatic down-regulation, resulting in decreased neurotransmission of dopamine, which can cause depression. Additionally, the post-synaptic actions of dopamine are mediated through G-protein coupled receptors. Once dopamine is coupled to the G-protein receptors, it stimulates other secondary messenger systems that modulate neurotransmission. Studies found that in autopsies (which do not necessarily reflect living people), people with bipolar disorder had increased G-protein coupling compared to people without bipolar disorder. Lithium treatment alters the function of certain subunits of the dopamine-associated G-protein, which may be part of its mechanism of action.

== Contraindications == In the US the only contraindication for tetracosactide for diagnostic use is hypersensitivity to ACTH but in the UK, regulators placed contraindications for hypersensitivity to ACTH and additionally, for people with allergic disorders including asthma, acute psychosis, infectious diseases, peptic ulcer, refractory heart failure, Cushing's syndrome, treatment of primary adrenocortical insufficiency and adrenocongenital syndrome. The same contraindications that were applied in the UK for diagnostic use of tetracosactide, apply for therapeutic use of both tetracosactide and corticotropin in the US and UK. In addition, the US label for corticotropin for therapeutic uses includes contraindications for people who have recently had surgery, and people with scleroderma, osteoporosis, uncontrolled hypertension, or sensitivity to proteins of porcine origin; in addition the infection diseases systemic fungal infection, ocular herpes simplex, and infants who have congenital infections are specified. The label also notes that people taking corticotropin for immunosuppression should not be given live vaccines.

leptonema Also leptotene stage. In meiosis, the first of five substages of prophase I, following interphase and preceding zygonema. During leptonema, the replicated chromosomes condense from diffuse chromatin into long, thin strands that are much more visible within the nucleus.

Sources: en.wikipedia.org

Frequently asked questions